Regenerative Regulatory
Keep abreast of the latest in stem cell and regenerative health developments with your go-to resource for understanding the evolving global landscape of regulations in regenerative medicine. As this innovative field continues to advance, countries worldwide are adopting diverse frameworks to ensure the safety, efficacy, and accessibility of regenerative therapies, including stem cell treatments, gene therapies, and tissue-engineered products. From the FDA’s expedited pathways in the U.S. to Japan’s fast-track approval systems and the European Union’s centralized processes for advanced therapies, this section explores how regulatory bodies are adapting to meet the challenges of this rapidly growing sector.
Explore the latest in regulatory poilicies
When stem cell clinics cross legal boundaries, the FDA doesn’t stay silent. From court-ordered shutdowns to public warning letters, the
"Homologous use" is a key term in FDA stem cell regulations. This post explains what it means, how it differs
The FDA’s stem cell laws, originally written in the 1990s, are struggling to keep up with today’s scientific advancements. This
The FDA’s standard of “minimal manipulation” is central to how stem cell products are regulated in the U.S. This post
What happens when states try to legalize stem cell treatments that the FDA hasn’t approved? This post explores whether state-level
Many stem cell clinics operate under what they believe is a legal exception known as the “same surgical procedure” rule.
Every stem cell clinic in the U.S. must struggle with a simple choice: are they operating under Section 361 or
Big news is shaking up the world of regenerative medicine: RFK Jr. has called for the fast-tracking and wider legalization
With stem cell therapies making headlines for everything from joint pain relief to anti-aging, it's easy to get swept up
Stem cell therapy is one of the most promising frontiers in medicine—but the U.S. legal framework surrounding it is murky,
The FDA has cleared Gameto’s iPSC-based therapy, Fertilo, for a Phase III clinical trial, marking a significant step in reproductive
Florida lawmakers have introduced groundbreaking legislation that could revolutionize access to umbilical cord stem cell therapies in the United States.
Tremfya (guselkumab) has been administered to a patient with ulcerative colitis for the first time. This FDA-approved treatment is offering